Literature DB >> 31734135

Prevalence of Positive QuantiFERON-TB Gold In-Tube Test in Uveitis and its Clinical Implications in a Country Nonendemic for Tuberculosis.

Fahriye Groen-Hakan1, Jan A M van Laar2, Marleen Bakker3, P Martin van Hagen2, Hannah Hardjosantoso4, Aniki Rothova4.   

Abstract

PURPOSE: To report on the prevalence and clinical implications of positive QuantiFERON-Gold (QFT-G) test results in the diagnostic evaluation of a large cohort of consecutive patients with uveitis in the Netherlands.
DESIGN: Retrospective cross-sectional study.
METHODS: This study included 710 consecutive patients who all underwent evaluation for uveitis including QFT-G testing. The ocular features, comorbidity, and abnormalities in diagnostic imaging and laboratory tests were registered for QFT-G-positive patients with uveitis.
RESULTS: Of all patients, 13% (92/710) were positive for QFT-G. Previously treated tuberculosis (TB) was documented in 2 patients. Of all 92 QFT-G-positive patients, culture-proven active TB was observed in 1 case. The proportion of patients with uveitis of unknown etiology was higher in QFT-G-positive than in the QFT-G-negative patients (54/92, 59% vs 238/618, 39%; P = .0004). The uveitis features of QFT-G-positive patients were mainly nonspecific. Of all QFT-G-positive patients with uveitis, 17 patients had chest imaging changes suggesting either TB or sarcoidosis. Twenty-nine QFT-G-positive patients with otherwise unexplained uveitis completed antituberculous therapy (29/710; 4% of all included patients) with beneficial effect in most cases.
CONCLUSION: The QFT-G tested positive in 13% of patients with uveitis in the Netherlands, whereas only sporadic patients had a documented previous or active TB infection. The proportion of patients with unexplained uveitis was higher in QFT-G-positive patients. Though the association between uveitis and a positive QFT-G test might be coincidental, the majority of treated QFT-G-positive patients with otherwise unexplained severe uveitis cause had a beneficial response to antituberculous therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31734135     DOI: 10.1016/j.ajo.2019.11.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Interferon-gamma release assays in tuberculous uveitis: a comprehensive review.

Authors:  Usanee Tungsattayathitthan; Sutasinee Boonsopon; Nattaporn Tesavibul; Tararaj Dharakul; Pitipol Choopong
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

2.  Absence of Evidence as The Evidence Of Absence: The Curious Case of Latent Infection Causing Ocular Tuberculosis.

Authors:  Soumyava Basu
Journal:  Front Ophthalmol (Lausanne)       Date:  2022-05-02

3.  The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States.

Authors:  Mehmet Yakin; Natasha Kesav; Shuk Kei Cheng; Sonny Caplash; Sapna Gangaputra; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2021-05-02       Impact factor: 5.488

Review 4.  BTS clinical statement for the diagnosis and management of ocular tuberculosis.

Authors:  Onn Min Kon; Nicholas Beare; David Connell; Erika Damato; Thomas Gorsuch; Guy Hagan; Felicity Perrin; Harry Petrushkin; Jessica Potter; Charanjit Sethi; Miles Stanford
Journal:  BMJ Open Respir Res       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.